Genworth Financial Inc Common Stock vs Veeva Systems — how do they compare? Genworth Financial Inc Common Stock trades at $8.82 (market cap $3.33B), while Veeva Systems trades at $297.89 (market cap $48.14B). The key difference: Veeva Systems is far larger — about 14.5× Genworth Financial Inc Common Stock's market cap, and Veeva Systems is trading nearer its 52-week high, Genworth Financial Inc Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Genworth Financial Inc Common Stock for 0 Days and Veeva Systems for 6 Days on average.
| GNW | VEEV | |
|---|---|---|
Market Cap | $3.33B | $48.14B |
Volume | 3,324,561 | 1,239,885 |
Sector | Financials | Technology |
52-Week High | $10.60 | $301.63 |
52-Week Low | $7.94 | $151.43 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.85B | $41.05B |
Signals from Pluang's Aura AI — not financial advice
Genworth Financial (GNW) trades at $8.89, down 1.77% today, with neutral technical signals and mixed fundamental performance. The company maintains stable revenue around $7.1-7.2B but faces margin pressure, with net income declining from $223M to $212M year-over-year. Recent Q2 2026 earnings beat expectations at $0.29 EPS, while the company expanded its share repurchase program by $500M in September 2026.
GNW presents value characteristics with low P/B (0.38) and P/S (0.49) ratios, but weak profitability metrics (ROE 2.42%) and analyst caution (70.59% hold rating) suggest limited near-term catalysts. Key risks include legacy insurance liabilities and competitive pressures, while the upcoming Q3 earnings on November 4 could provide directional clarity.
Veeva Systems (VEEV) trades at $301.63, up 1.95% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 74.96% gross margins and consistent earnings beats, while expanding partnerships with IQVIA and Servier enhance growth prospects. Recent news highlights AI innovations and increasing adoption among biotech firms, supporting positive sentiment.
Outlook remains favorable with analyst consensus at Buy (67% rating) and $290.50 price target, though valuation multiples appear elevated. Key risks include market saturation concerns and potential volatility from RSI overbought signals. The stock's proximity to 52-week highs suggests continued investor confidence in Veeva's life sciences software leadership.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Genworth Financial, Inc. is a holding company that provides products and services related to aging and long-term care planning, and is the parent company of publicly traded mortgage insurer Enact Holdings, Inc.
Read more on GNW →Veeva Systems provides cloud software, data, and services for the life sciences industry. Its applications support functions across clinical research, regulatory operations, quality, safety, and commercial teams.
Read more on VEEV →